STOCK TITAN
  1. Home
  2. News
  3. REGN

Regeneron Pharmaceuticals Inc - REGN STOCK NEWS

Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.

Regeneron Pharmaceuticals Inc. (symbol: REGN) is a prominent American biotechnology company headquartered in Westchester County, New York, since its founding in 1988. The core mission of Regeneron is to discover, develop, and commercialize innovative products targeting a range of serious medical conditions. With a diverse portfolio, Regeneron focuses on therapies for eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.

Among its marketed products, Eylea stands out as a treatment for wet age-related macular degeneration and other eye diseases. Praluent is designed to lower LDL cholesterol levels, while Dupixent addresses multiple immunological conditions. In the oncology sector, Libtayo is a key therapy, and Kevzara targets rheumatoid arthritis.

The company is also heavily invested in the development of monoclonal and bispecific antibodies, often in collaboration with Sanofi and other partners. These initiatives include cutting-edge technologies such as RNA interference (RNAi) with Alnylam and CRISPR-based gene editing with Intellia.

Regeneron's recent progress includes significant advancements in its clinical-stage pipeline, which comprises over 35 product candidates. The company's financial health remains robust, supported by strong revenue streams from collaboration with Sanofi and a strategic $3.0 billion share repurchase program authorized by the board.

Latest updates highlight the company's ongoing efforts in gene therapy, particularly in treating genetic deafness and solid tumors. Regeneron's commitment to pioneering genetic medicine and leveraging data insights from the Regeneron Genetics Center® positions it as a leader in the biopharmaceutical industry.

For more information, visit Regeneron Pharmaceuticals.

News

Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)

Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is increasing and extending its commitment as the title sponsor of the Regeneron International Science and Engineering Fair (ISEF), the world’s largest high school science and engineering competition, with a total investment of approximately $34 million over a five-year period. Established in 1950, Regeneron ISEF gives young scientists a global stage to share their outstanding STEM research and compete for nearly $8 million in awards, prizes, and scholarships. The renewed sponsorship builds on Regeneron and the Society's long-standing partnership to advance STEM education, including through Regeneron's $100 million, ten-year commitment to the Regeneron Science Talent Search (STS), the nation’s oldest and most prestigious high school science and mathematics competition. The increased investment will raise the top ISEF award, the George D. Yancopoulos Innovator Award, to $100,000, the two second place awards, the Regeneron Young Scientist Awards, to $75,000 each, and increase all category awards by 20 percent. Since assuming title sponsorship in 2019, Regeneron ISEF has welcomed over 5,000 high school students representing 64 countries and distributed a total of nearly $22 million in awards, prizes, and scholarships to the top young scientists in the world.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
-
News

Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH

Rhea-AI Summary
Regeneron Pharmaceuticals will be sharing new and updated data from its hematology pipeline at the American Society of Hematology (ASH) Annual Meeting. The data includes research on six investigational medicines for eight difficult-to-treat blood cancers and disorders. Key presentations will focus on odronextamab in follicular lymphoma and diffuse large B-cell lymphoma, as well as linvoseltamab in multiple myeloma. Odronextamab is currently under regulatory review, and linvoseltamab will present primary endpoint results with longer follow-up.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
-
News

Regeneron Reports Third Quarter 2023 Financial and Operating Results

Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. reported a 15% increase in revenues to $3.36 billion in the third quarter of 2023. Dupixent global net sales increased by 33% to $3.10 billion, while U.S. net sales for EYLEA and EYLEA HD were $1.49 billion. The company also announced the FDA approval of EYLEA HD for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, as well as the FDA acceptance for priority review of odronextamab for follicular lymphoma and diffuse large B-cell lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
earnings
News

EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema

Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. will present long-term outcomes and new analyses of pivotal clinical data for EYLEA HD (aflibercept) Injection 8 mg at the American Academy of Ophthalmology annual meeting. The presentations will highlight the durability of visual improvements and consistent safety of EYLEA HD across extended dosing intervals and patient characteristics. Notable presentations include positive two-year results from trials in wet age-related macular degeneration and diabetic macular edema, as well as subgroup data and safety analysis. EYLEA HD is being jointly developed by Regeneron and Bayer AG.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
none
-
News

Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

Rhea-AI Summary
Regeneron Pharmaceuticals announces positive preliminary results from Phase 1/2 CHORD trial investigating otoferlin gene therapy for children with genetic hearing loss
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
none
-
News

Regeneron Announces Investor Conference Presentations

Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will be participating in several upcoming biopharma conferences and webcasting the sessions. The webcasts will be available on the company's website and replays will be archived for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
none
News

Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)

Rhea-AI Summary
Regeneron and Sanofi announce positive results from a Phase 3 trial of Dupixent in children with eosinophilic esophagitis (EoE)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)

Rhea-AI Summary
Regeneron Pharmaceuticals announces positive results for Libtayo in the treatment of cutaneous squamous cell carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria

Rhea-AI Summary
Regeneron and Sanofi receive Complete Response Letter from FDA for Dupixent in chronic spontaneous urticaria
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
none
News

Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN

Rhea-AI Summary
Regeneron Pharmaceuticals announces a $5 million strategic investment to support Nashville's STEM ecosystem through engagement programs for students and teachers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
none

FAQ

What is the current stock price of Regeneron Pharmaceuticals (REGN)?

The current stock price of Regeneron Pharmaceuticals (REGN) is $762 as of November 18, 2024.

What is the market cap of Regeneron Pharmaceuticals (REGN)?

The market cap of Regeneron Pharmaceuticals (REGN) is approximately 83.4B.

What types of diseases does Regeneron Pharmaceuticals focus on?

Regeneron focuses on eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.

What are some of Regeneron's key products?

Key products include Eylea for eye diseases, Praluent for lowering LDL cholesterol, Dupixent for immunology, Libtayo for oncology, and Kevzara for rheumatoid arthritis.

Who are some of Regeneron's notable collaborators?

Regeneron collaborates with Sanofi, Alnylam, and Intellia on various projects, including monoclonal and bispecific antibodies, RNAi, and CRISPR-based gene editing.

What recent financial steps has Regeneron taken?

Regeneron has initiated a $3.0 billion share repurchase program and reported strong financial performance in the first quarter of 2024.

How does Regeneron leverage genetic medicine?

Regeneron utilizes data-powered insights from the Regeneron Genetics Center® and employs proprietary technologies like VelociSuite® to advance drug development.

What is the significance of Eylea in Regeneron's product portfolio?

Eylea is a crucial product for treating wet age-related macular degeneration and other eye diseases, contributing significantly to Regeneron's revenue.

What advancements has Regeneron made in gene therapy?

Regeneron is progressing in gene therapy for genetic deafness and solid tumors, showcasing promising early results in clinical trials.

What is Dupixent used for?

Dupixent is used in treating various immunological conditions and has shown significant growth since its launch, treating over 850,000 patients.

What technologies does Regeneron use for drug development?

Regeneron uses proprietary technologies such as VelociSuite®, which includes platforms for producing optimized human antibodies and bispecific antibodies.

How does Regeneron contribute to scientific discovery?

Regeneron pushes the boundaries of scientific discovery with pioneering genetic medicine platforms and data insights, aiming to develop transformative therapies.

Stock REGN logo
Regeneron Pharmaceuticals Inc

Nasdaq:REGN

REGN Rankings

#160 Ranked by Market Cap
N/A Ranked by Dividends

REGN Stock Data

83.39B
108.07M
1.56%
91%
1.56%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
TARRYTOWN